Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 355

Results For "treatment"

3713 News Found

Alembic JV Aleor receives US FDA final approval for skin disorder gel
Drug Approval | September 06, 2021

Alembic JV Aleor receives US FDA final approval for skin disorder gel

Metronidazole Gel USP, 1% is indicated for the topical treatment of inflammatory lesions of rosacea


Bajaj Healthcare gets a go-ahead for 2-Deoxy-D-Glucose to treat Covid-19
Drug Approval | September 06, 2021

Bajaj Healthcare gets a go-ahead for 2-Deoxy-D-Glucose to treat Covid-19

Marketed under the brand name DGJAJ, it helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence


TB Alliance partners with Lupin for non-exclusive anti-TB drug
Policy | September 06, 2021

TB Alliance partners with Lupin for non-exclusive anti-TB drug

According to WHO, over 1.5 million people died of TB in 2020


DGCI approves Hetero’s Tocilizumab
Drug Approval | September 06, 2021

DGCI approves Hetero’s Tocilizumab

Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month


Govt revises NLEM and slashes prices of 39 drugs
Policy | September 04, 2021

Govt revises NLEM and slashes prices of 39 drugs

At present 18 per cent of the local pharmaceutical market is under government's price control


HCG acquires oncology labs and divests stake in Strand Life Sciences
Healthcare | September 04, 2021

HCG acquires oncology labs and divests stake in Strand Life Sciences

The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business


Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent
Drug Approval | September 04, 2021

Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent

In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.


Novartis signs world’s first agreement with NHS, UK
News | September 03, 2021

Novartis signs world’s first agreement with NHS, UK

The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England


Natco Pharma launch Nat-Lenalidomide in Canada
Drug Approval | September 02, 2021

Natco Pharma launch Nat-Lenalidomide in Canada

Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)


Janssen announces U.S. FDA approval of Invega Hafyera
Drug Approval | September 02, 2021

Janssen announces U.S. FDA approval of Invega Hafyera

Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months